July 9, 2020Open Access

Cost-effectiveness of surgery for drug-resistant temporal lobe epilepsy in the US

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

For surgically eligible patients with DR-TLE, surgery is cost-effective. For patients with DR-TLE in general, referral for surgical evaluation (and possible subsequent surgery) is cost-effective. Patients with DR-TLE should be referred for surgical evaluation without hesitation on cost-effectiveness grounds.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Sheikh et al. (Thu,) studied this question.

synapsesocial.com/papers/69d76490aa68b335b4f31311 https://doi.org/https://doi.org/10.1212/wnl.0000000000010185

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Epilepsy Surgery for Pharmacoresistant Temporal Lobe Epilepsy2008 · 187 citations
2Testing the Validity of Cost-Effectiveness Models2000 · 98 citations
3The Cost of Epilepsy in the United States: An Estimate from Population‐Based Clinical and Survey Data2000 · 607 citations
4Health‐Related Quality of Life Outcome in Medically Refractory Epilepsy Treated with Anterior Temporal Lobectomy2000 · 168 citations
5Medication Management after Epilepsy Surgery: Opinions versus Facts2013 · 11 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo